PET/MRI Evaluation of Cardiac Amyloid

Status Completed

Clinical Trial Summary

Cardiac amyloidosis is a disorder characterized by the deposition of abnormal proteins called amyloid in the heart tissue. This makes it difficult for the heart to function properly. The investigators wish to evaluate if the radiopharmaceutical 18F‑Florbetaben (Neuraceq®) that targets beta amyloid can also identify cardiac amyloid deposition.

Clinical Trial Description

The use of hybrid positron emission tomography/ magnetic resonance imaging (PET/MRI) scanners in clinical practice enhance the ability to evaluate the heart from both an anatomical and functional perspective. It is hypothesized that an increased PET signal of 18F‑Florbetaben (Neuraceq®) will be detected in cardiac amyloid deposits within the heart tissue, while the MRI provides the anatomical information. The ability to reliably and non-invasively image amyloid deposition in the heart would be potentially advantageous in the following scenarios:

1. Diagnosis of cardiac amyloidosis

2. Decreasing unnecessary invasive myocardial procedures.

The investigators believe this trial will help expand the use of current PET amyloid tracers and help many patients who currently undergo myocardial biopsy for the diagnosis of cardiac amyloid. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03119558
Study type	Interventional
Source	Stanford University
Contact
Status	Completed
Phase	Early Phase 1
Start date	May 26, 2016
Completion date	August 28, 2018

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04459169` - Cardiac Amyloidosis : Diagnostic Using Red Flag Signals
Recruiting	`NCT03029026` - The Role of Occult Cardiac Amyloid in the Elderly With Aortic Stenosis.
Recruiting	`NCT06034405` - Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis
Recruiting	`NCT04915235` - Prevalence and Prognosis of Cardiac Amiloidosis in Turkey
Recruiting	`NCT02966522` - Thalidomide/Dexamethasone Treatment And PET Evaluation In Organ Involvemenet of Cardiac Amyloidosis	Phase 2
Terminated	`NCT03333551` - Cardiac Uptake of 18F Florbetapir in Patients Undergoing Chemotherapy	Phase 4
Recruiting	`NCT04105634` - Molecular Imaging of the Underlying Mechanism of Cardiotoxicity in Patients With Light Chain Amyloidosis Using PET/CT	Early Phase 1
Recruiting	`NCT05139797` - Artificial Intelligence Guided Echocardiographic Screening of Rare Diseases (EchoNet-Screening)
Not yet recruiting	`NCT05593679` - A Multi-center Cardiac PYP Scan Registry in Taiwan.
Not yet recruiting	`NCT04146415` - Diagnosis of Cardiac Amyloidosis With 99mTc-PYP; Comparison Between Planar Imaging, SPECT/CT and Cardiac-dedicated CZT Camera	N/A
Recruiting	`NCT03626584` - PET/MR Imaging In Patients With Cardiac Amyloidosis
Recruiting	`NCT04856267` - Exploration of Arrhythmia Burden in Cardiac Amyloidosis Using Implantable Loop Recorders
Recruiting	`NCT02798705` - Physiologic Assessment of Microvascular Function in Patients With Cardiac Amyloidosis
Not yet recruiting	`NCT04387344` - Morpho-functional Cardiac Modifications in Treated Mutated Transthyretin Cardiac Amyloidosis
Recruiting	`NCT06129656` - Cardiac Amyloidosis Registry of University Hospital Leipzig
Terminated	`NCT01683825` - Imaging Cardiac Amyloidosis: A Pilot Study Using F-18 Florbetapir Positron Emission Tomography	Phase 4
Withdrawn	`NCT04363294` - Targeted Testing for ATTR Among Aortic Stenosis Patients-Pilot	N/A
Not yet recruiting	`NCT04661800` - Study of Olfactory Disorders in Patients With Cardiac Amyloidosis	N/A
Terminated	`NCT03232632` - Assessment of Cardiac Fixation During PET Using a New Drug Within Amyloid Cardiac Injuries.	Early Phase 1
Recruiting	`NCT04830696` - 3D ECG for Detection of Cardiomyopathy